Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Hiroyuki Kurebe"'
Autor:
Satoshi Tobita, Yuhei Kinehara, Yoshio Tamura, Hiroyuki Kurebe, Ryusuke Ninomiya, Yoshihiko Utsu, Satoshi Kohmo, Bunzo Sato, Kenichi Nagai, Shintaro Maruoka, Ryu Jokoji, Shohei Koyama, Isao Tachibana
Publikováno v:
Thoracic Cancer, Vol 11, Iss 8, Pp 2357-2360 (2020)
Abstract The patient in this report was a 57‐year‐old man with metastatic non‐small cell lung cancer (NSCLC). After no response to two lines of systemic chemotherapy, he was treated with nivolumab as third‐line therapy, which resulted in a pa
Externí odkaz:
https://doaj.org/article/baeb5b8a2f044552b2bb507511a6f809
Autor:
Keisuke Miki, Mari Miki, Kenji Yoshimura, Kazuyuki Tsujino, Hiroyuki Kagawa, Yohei Oshitani, Yuko Ohara, Yuki Hosono, Ryuya Edahiro, Hiroyuki Kurebe, Seigo Kitada
Publikováno v:
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Abstract Background Bronchial thermoplasty (BT) is a bronchoscopic treatment that can ameliorate the symptoms of severe asthma. However, little is known about the mechanism by which BT improves exertional dyspnea without significantly changing the re
Externí odkaz:
https://doaj.org/article/8bec2672cf2c463698410614edeb6699
Autor:
Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, Masahide Mori, Daichi Fujimoto, Yoshihiko Taniguchi, Hidekazu Suzuki, Katsuya Hirano, Toshihide Yokoyama, Mitsunori Morita, Yasushi Fukuda, Junji Uchida, Takeshi Makio, Motohiro Tamiya
Publikováno v:
PLoS ONE, Vol 14, Iss 7, p e0220570 (2019)
BackgroundPembrolizumab is currently approved as a first-line therapy for advanced non-small cell lung cancer (NSCLC) patients with a programed death ligand-1 (PD-L1) expression ≥50%. However, the association between the efficacy of pembrolizumab a
Externí odkaz:
https://doaj.org/article/d678a2452d374149aef1f73ebb67e5df
Autor:
Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, Yuki Hosono, Saeko Nakatsubo, Kohei Nishida, Nobuyuki Sawa, Mikako Ishijima, Takeshi Uenami, Masaki Kanazu, Yuki Akazawa, Toshihiko Yamaguchi, Masahide Mori
Publikováno v:
PLoS ONE, Vol 13, Iss 8, p e0203070 (2018)
OBJECTIVES:The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated. The aim of the present study was to clarify the clinical benefit of post-nivolumab tre
Externí odkaz:
https://doaj.org/article/41315e8500084efd850d355235761587
Autor:
Hiroyuki Kurebe, Bunzo Sato, Ryu Jokoji, Yoshihiko Utsu, Yoshio Tamura, Ryusuke Ninomiya, Shintaro Maruoka, Shohei Koyama, Isao Tachibana, Kenichi Nagai, Yuhei Kinehara, Satoshi Kohmo, Satoshi Tobita
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 8, Pp 2357-2360 (2020)
Thoracic Cancer, Vol 11, Iss 8, Pp 2357-2360 (2020)
The patient in this report was a 57‐year‐old man with metastatic non‐small cell lung cancer (NSCLC). After no response to two lines of systemic chemotherapy, he was treated with nivolumab as third‐line therapy, which resulted in a partial res
Autor:
Yohei Oshitani, Seigo Kitada, Saeko Nakatsubo, Kazuyuki Tsujino, Masahide Mori, Kohei Nishida, Yuko Ohara, Kenji Yoshimura, Nobuhiko Sawa, Keisuke Miki, Hiroyuki Kagawa, Mari Miki, Yuki Hosono, Hiroyuki Kurebe, Ryuya Edahiro
Publikováno v:
Internal Medicine
Diffuse pulmonary ossification (DPO) is an uncommon diffuse lung disease characterized by metaplastic bone formation in the lung parenchyma and is rarely diagnosed in life. While DPO usually occurs as a secondary disease, idiopathic cases are extreme
Autor:
Yuko Ohara, Yohei Oshitani, Mari Miki, Hiroyuki Kurebe, Keisuke Miki, Hiroyuki Kagawa, Kazuyuki Tsujino, Seigo Kitada, Kenji Yoshimura, Ryuya Edahiro, Yuki Hosono
Publikováno v:
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Allergy, Asthma & Clinical Immunology, Vol 14, Iss 1, Pp 1-5 (2018)
Background Bronchial thermoplasty (BT) is a bronchoscopic treatment that can ameliorate the symptoms of severe asthma. However, little is known about the mechanism by which BT improves exertional dyspnea without significantly changing the resting pul
Autor:
Ryuya Edahiro, Ryoji Maekura, Kenji Yoshimura, Yuki Hosono, Seigo Kitada, Keisuke Miki, Yohei Oshitani, Hiroyuki Kurebe, Yuko Ohara, Kazuyuki Tsujino, Mari Miki, Hiroyuki Kagawa
Publikováno v:
Clinical respiratory physiology, exercise and functional imaging.
Rationale: Little is known about the applicability of respiratory muscle training based on exertional conditions in chronic obstructive pulmonary disease (COPD) patients. The aim of this study was to investigate the relationship between breathing tim
Autor:
Yohei Oshitani, Kenji Yoshimura, Ryoji Maekura, Hiroyuki Kurebe, Yuko Ohara, Seigo Kitada, Mari Miki, Yuki Hosono, Keisuke Miki, Hiroyuki Kagawa, Ryuya Edahiro, Kazuyuki Tsujino
Publikováno v:
Journal of breath research. 12(3)
Rationale Little is known about the applicability of respiratory muscle training based on exertional pathophysiological conditions in patients with chronic obstructive pulmonary disease (COPD). The aim of this study was to investigate the relationshi
Autor:
Yoko Akaike, Kentaro Kita, Yuki Kuwano, Chihiro Nishiyama, Kensei Nishida, Kazuhito Rokutan, Hiroyuki Kurebe, Shizuka Kano, Ken Kurokawa, Keishuke Kajita, Kiyoshi Masuda, Toshihito Tanahashi
Publikováno v:
American Journal of Physiology-Cell Physiology. 306:C250-C262
Serine/arginine-rich splicing factor 3 (SRSF3) is a member of the SR protein family and plays wide-ranging roles in gene expression. The human SRSF3 gene generates two alternative splice transcripts, a major mRNA isoform ( SRSF3-FL) encoding function